Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.51 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.49 |
| ▸ | DUS2 | Q9NX74 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 16/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27139860 | 0.93 | EGFR (0.53) | EGFRERBB3DUS2KDR | |
| SCHEMBL24714506 | 0.92 | EGFR (0.49) | EGFRERBB3DUS2KDR | |
| SCHEMBL30822153 | 0.92 | EGFR (0.49) | EGFRERBB3DUS2KDR | |
| SCHEMBL24714723 | 0.90 | EGFR (0.52) | EGFRERBB3DUS2KDR | |
| SCHEMBL24713933 | 0.90 | EGFR (0.51) | EGFRERBB3DUS2KDR | |
| SCHEMBL24714969 | 0.87 | EGFR (0.63) | EGFRERBB3DUS2KDR | |
| SCHEMBL30030882 | 0.85 | EGFR (0.55) | EGFRERBB3DUS2KDR | |
| SCHEMBL24714950 | 0.85 | EGFR (0.55) | EGFRERBB3DUS2KDR | |
| SCHEMBL24714738 | 0.83 | EGFR (0.49) | EGFRKDR | |
| SCHEMBL24715219 | 0.80 | EGFR (0.50) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4328222-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | Voronoi Inc. (KR) | 2024-02-28 | — | — | EP | claimed |
| US-20240246940-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC. (KR) | 2024-07-25 | — | — | US | disclosed |
| EP-4328222-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | Voronoi Inc. (KR) | 2024-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246940-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | ERBB2, EGFR, ERBB3 | EGFR 2/4885ERBB3 3/4885DUS2 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.